Article Text

other Versions

PDF
Correspondence
Resolution of post-polycythaemic myelofibrosis with a combination of thalidomide and interferon
  1. Sangam Hebballi1,
  2. Susanna Akiki2,
  3. David Bareford1
  1. 1Department of Haematology, Russells Hall Hospital, Dudley, UK
  2. 2Department of Molecular Genetics, West Midlands Regional Genetics Laboratory, Birmingham, UK
  1. Correspondence to Dr David Bareford, Department of Haematology, Russells Hall Hospital, Dudley, DY1 2HQ, UK; d.bareford{at}bham.ac.uk

Statistics from Altmetric.com

A middle-aged woman developed myelofibrosis secondary to polycythaemia vera (PV) while on hydroxycarbamide. She responded successfully to medical therapy—a combination of thalidomide and interferon (IFN). She continues to be in controlled chronic phase polycythaemia after 4 years of diagnosis of myelofibrosis and is on a single agent pegylated (peg)-IFNα-2a.

Case report

At the age of 45 years, the patient was diagnosed with primary polycythaemia based on haemoglobin (Hb) 22 g/dl, histological appearances of the bone marrow (figure 1A,B) and absence of other causes. JAK2 mutation analysis was not routinely available at that time. Due to intolerance to venesection, she received treatment with hydroxycarbamide with good control of cell counts. After 7 years (then aged 52 years) she developed anaemia, Hb 9.4 g/dl, which did not improve after cessation of hydroxycarbamide and bone marrow examination surprisingly showed aggressive myelofibrosis secondary to PV (figure 1C,D). The JAK2 status was checked and it was found positive for V516F, with a JAK2V516F/total JAK2 ratio of 31%.

Figure 1

Bone marrow histology with H&E stain in the top row …

View Full Text

Request permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.